logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Presents Data From Phase IIb Trial In Patients With Refractory NSCLC

Peregrine Pharmaceuticals Inc. (PPHM) announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer or NSCLC.

The company noted that the blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm). The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival or OS in the bavituximab-containing arms compared to the control arm.

The trial enrolled 121 patients (117 evaluable per the study protocol) with second-line non-squamous NSCLC following one prior chemotherapy regimen at over 40 clinical centers. Patients were equally randomized to 1 of the 3 treatment arms, docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression. Approximately 50% of the patients were enrolled in the U.S. and 50% were enrolled internationally with equal distribution between all treatment groups.

The company noted that the interim results from the study showed no significant safety differences between the three treatment arms as determined by the trial's independent data monitoring committee. Baseline characteristics were well balanced across all three treatment arms of the study, including performance or ECOG status, age, gender, and race. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on blinded central radiology review.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Deutsche Bank AG declined around 4 percent in the morning trading after the German bank reported Wednesday sharply lower profit in its second quarter with significant one-time charges as well as weak revenues. John Cryan, CEO, said,".. if the current weak economic environment persists, we will need to be yet more ambitious in the timing and intensity of our restructuring." Shares of Airbus Group SE were gaining around 6 percent in the early morning trading in Paris after the aerospace and defense major reported Wednesday significantly higher profit in its second quarter, with positive one-offs items. Revenues, meanwhile, declined 1 percent with weakness in all segments. For fiscal 2016, the company continues to expect stable earnings per share. Shares of Apple Inc. (AAPL) gained 5 percent in extended trading session after the tech giant reported a third-quarter profit and revenues that trumped Wall Street expectations driven by higher-than-expected iPhone sales. Although, Apple reported its second year-over-year decline in iPhone sales,...
comments powered by Disqus
Follow RTT